Compare Vanguard High Dividend Yield ETF (VYM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs GeneDx Holdings Corp — how do they compare? Vanguard High Dividend Yield ETF trades at $158.52 (market cap $100.80B), while GeneDx Holdings Corp trades at $69.07 (market cap $2.02B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 49.9× GeneDx Holdings Corp's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard High Dividend Yield ETF for 138 Days and GeneDx Holdings Corp for 19 Days on average.
| VYM | WGS | |
|---|---|---|
Market Cap | $100.80B | $2.02B |
Volume | 908,176 | 734,640 |
52-Week High | $167.03 | $167.51 |
52-Week Low | $137.47 | $34.51 |
Typical Hold Time | 138 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $158.56, up 0.7% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD and IDV. Support sits at $156, with resistance at $159-160. Recent news questions its stock selection methodology after holding Intel and Walgreens through dividend cuts.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include sector concentration in dividend-cut-prone stocks and inflation persistence. Opportunities lie in its low expense ratio and broad diversification across nearly 600 holdings for income-focused investors.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
